BerGenBio - Focusing in on 1L NSCLC and COVID-19
BerGenBio (BGBIO) has announced an updated business strategy for its lead drug candidate, oral AXL inhibitor bemcentinib, which will focus on first-line (1L) non-squamous non-small cell lung cancers (NSCLCs) carrying the STK11 mutation and on hospitalised COVID-19 patients. The decision to move bemcentinib to the 1L setting could significantly broaden its target population among NSCLCs, given that c 20% of such cancers carry the STK11 mutation (~30,000 patients). Following encouraging data from the Phase II ACCORD2 study, BGBIO will continue to pursue bemcentinib in the treatment of hospitalised COVID-19 patients, with the EU-SolidAct platform trial set to begin recruitment shortly in a sub-protocol arm designed to enrol 500 patients across European sites. With this news we expect the company to deprioritise the current clinical development of bemcentinib in second-line (2L) NSCLC and 2L AML to focus on these new opportunities, which management sees as offering significant value potential. Our forecasts are under review.BerGenBio is a clinical stage biopharmaceutical company focused on developing innovative drugs for aggressive, drug resistant cancers. Co.'s lead product, BGB324, is a selective, potent and orally available small molecule AXL inhibitor. It is in Phase II clinical development, as a single agent and in combination with marketed immuno-oncology drugs, in three cancer indications with potential: Acute myeloid leukaemia; Advanced non-small-cell lung cancer and Triple negative breast cancer. Co. is also developing a diversified pre-clinical pipeline of selective AXL inhibitors, including biologics and small molecules.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.